SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DOSE(capstone pharm)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MARK BARGER who wrote (2)2/9/1998 4:56:00 PM
From: Toby Zidle  Read Replies (2) of 92
 
Lantern & Co. is cold-calling on this stock today.

I just got a call from a rep at Lantern & Co. soliciting orders for DOSE. The story given is that, given a strong program of acquisitions and strong earnings announced today, the stock is about to break out with a target of $20-25 in a short time. Allegedly, DOSE is trading at a P/E that is about half of the overall industry.

Earnings came out at 12 cents today which, according to Zacks (1/31), would be a penny under consensus.

When I told the sales rep I wouldn't place an order on a company I hadn't checked out, the sales pitch got a bit hotter. I was told that I'd only find out info relating to past performance, but for future performance, I'd have to trust someone in the know like him. Hmmmm!

Well, from reading this thread and looking at a chart, I'd conclude that DOSE may have some promise. A lot of analysts thinks so too. But DOSE sure will have a rough time getting through the $13 resistance. Rate this stock a B-.

And......... let the buyer beware!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext